Mentari Therapeutics, a clinical-stage biotechnology company developing treatments for migraine prevention, has completed its merger with InMed Pharmaceuticals following approximately $490 million in private financing transactions.
The combined company will operate under the Mentari Therapeutics name, with its shares expected to begin trading on the Nasdaq Capital Market under the ticker symbol MTRI on November 9, 2026.
The transaction provides Mentari with a publicly traded corporate structure and financial resources to advance its development pipeline.
Before the merger closed, the privately held Mentari completed previously announced financing transactions totaling approximately $490 million in gross proceeds.
The total included the conversion of $50 million in previously issued convertible notes and accrued interest.
InMed also completed its redomiciliation from British Columbia, Canada, to Nevada before closing the business combination.
Under the merger agreement, outstanding shares of privately held Mentari were converted into approximately 0.20065 shares of the combined company’s common stock, reflecting adjustments associated with a one-for-10 reverse stock split completed on November 4.
InMed shareholders of record as of November 5 received one non-transferable contingent value right for each share they held.
Mentari is headquartered in Waltham, Massachusetts, and focuses on developing next-generation biologic medicines for migraine prevention.
Migraine affects more than one billion people worldwide and can cause recurrent headaches accompanied by neurological symptoms, nausea, and sensitivity to light or sound.
The company’s lead programs target biological pathways involved in migraine development.
Its first candidate, MT-001, is an anti-PACAP monoclonal antibody designed to prevent migraine by targeting pituitary adenylate cyclase-activating polypeptide.
PACAP is a signaling molecule associated with migraine biology and represents a therapeutic target distinct from approaches focused solely on calcitonin gene-related peptide.
Mentari’s second program, MT-002, is a bispecific antibody designed to target both PACAP and CGRP.
The company believes combining these mechanisms may offer potential benefits for patients who experience incomplete responses to existing migraine prevention therapies.
Both programs were originally discovered by Paragon.
Mentari is pursuing a strategy of developing differentiated treatments targeting established migraine-related biological pathways.
The company intends to use its financial resources and public market access to support clinical development and advance its portfolio.
The merger represents a corporate transition from InMed Pharmaceuticals to Mentari Therapeutics, with the combined company focused on migraine drug development.
Its upcoming Nasdaq trading under the MTRI symbol will mark the next stage of that transition.
The company will continue working toward clinical milestones for MT-001 and MT-002, although their effectiveness, safety, and eventual regulatory outcomes remain subject to clinical evaluation.

